GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » Institutional Ownership

Athersys (FRA:4LSA) Institutional Ownership : 4.11% (As of May. 29, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Athersys Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Athersys's institutional ownership is 4.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Athersys's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Athersys's Float Percentage Of Total Shares Outstanding is 98.44%.


Athersys Institutional Ownership Historical Data

The historical data trend for Athersys's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Institutional Ownership Chart

Athersys Historical Data

The historical data trend for Athersys can be seen below:

2023-01-31 2023-02-28 2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31
Institutional Ownership 7.36 7.65 8.11 7.10 6.40 7.00 6.97 5.69 4.11 4.11

Athersys Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Athersys (FRA:4LSA) Business Description

Traded in Other Exchanges
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Athersys (FRA:4LSA) Headlines

No Headlines